In summary, although the exact effect of denosumab in bone metastasis disease should be identified in future studies, denosumab does indicate that the RANK/RANKL signalling pathway, as an important signalling pathway for the establishment of the PMN in bone, can be targeted to improve the bone metastasis-related outcomes of patients with aggressive tumours. Here, TNFSF11 is linked to neoplasm.